{"id":2301,"date":"2013-10-28T19:00:00","date_gmt":"2013-10-28T23:00:00","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies\/coming-soon\/"},"modified":"2018-11-06T20:41:24","modified_gmt":"2018-11-07T01:41:24","slug":"coming-soon","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/medicine\/infdis\/actu\/current-studies-2\/coming-soon\/","title":{"rendered":"Coming Soon"},"content":{"rendered":"

HIV CURE-related Studies<\/strong><\/span><\/h3>\n

A5369<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nTo evaluate the safety and tolerability of two different HIV vaccines. To see if the vaccines improve the immune system\u2019s ability to fight HIV.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHIV-infected men and women on ART with HIV-1 RNA <50 for \u2265 2 years, current CD4 >500, and nadir CD4 >350.<\/td>\n<\/tr>\n
Medication<\/strong><\/td>\np24CE1\/2 pDNA vaccine and\/or full-length p55gag pDNA vaccine<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\n48 weeks<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\nVisits – $50, Optional Leukapheresis Procedure(s) – $150, Total – $600- $900. Travel & parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

VOR-07<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nTo evaluate the safety and tolerability of combination therapy with VRC07-523LS and VOR in HIV-infected participants on cART.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHealthy men and women of any race with HIV-1 infection, ages 18 through 64, suppressed on ART therapy for > 24 months. Eligible participants must have a CD4 cell count \u2265 300 cells\/mm3.<\/td>\n<\/tr>\n
Medication<\/strong><\/td>\nVorinostat and VRC07-523LS<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\n36 weeks<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\nTotal – $2850. Travel & parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A5357<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nLong-Acting Cabotegravir + VRC01LS is safe and will keep patient\u2019s HIV virus suppressed.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHIV infected men and women\u00a0 \u2265 18 years of age. CD4 \u2265 350, HIV RNA < 50 for 2 years.<\/td>\n<\/tr>\n
Medication<\/strong><\/td>\nOral and injectable Cabotegraivir and VRC01LS Infusions<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\nStep 1- 9 weeks: Step 2- 48 weeks: Step 3- 48 weeks<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\nStep 1: $300; Step 2: $1,600; Step 3 $300. Travel & parking compensation are offered as well.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The M & M Study<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nSafety and ability of 2 different HIV vaccines to provoke an immune response within the body.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHIV infected men and women 18-60 years of age. CD4 \u2265 350, HIV RNA < 50 for 2 years.<\/td>\n<\/tr>\n
Medication<\/strong><\/td>\n2 HIV vaccines: MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4)<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\n4 months<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

<\/h3>\n

HIV Treatment & Overall Health Studies<\/strong><\/span><\/h3>\n

A5359<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nHIV treatment using Long-Acting injectable ART will be a more successful therapy compared to a Standard of Care oral ART regimen in keeping previously non-adherent, HIV-infected individuals on treatment and virologically suppressed.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHIV infected men and women\u00a0\u2265 18 years of age. HIV<\/p>\n

RNA > 200 copies\/mL, non-adherent to HIV medication.<\/td>\n<\/tr>\n

Medication<\/strong><\/td>\nOral and Long-Acting injectable Cabotegravir and Rilpivirine<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\nUp to 3.5 years<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

GS-US-380-4580<\/h3>\n\n\n\n\n\n\n\n
Goal<\/strong><\/td>\nEffectiveness of switching from an ART regimen of 2 NRTIs and a third agent to Bictegravir, a fixed dose combination.<\/td>\n<\/tr>\n
Who is eligible to participate<\/strong><\/td>\nHIV infected men and women\u00a0\u2265 18 years of age who self-describe as Black, African American, or mixed race, including Black. HIV RNA < 50 copies\/mL, on a stable regimen of two NRTIs and a third agent for \u2265 6 months prior to screening.<\/td>\n<\/tr>\n
Medication<\/strong><\/td>\nBictegravir<\/td>\n<\/tr>\n
Duration<\/strong><\/td>\nAt least 48 weeks<\/td>\n<\/tr>\n
Compen<\/strong>sation<\/strong><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n